BioPorto commences process to appoint new Chair of the Board of Directors
16 déc. 2024 12h53 HE
|
BioPorto A/S
December 16, 2024 Announcement no. 23 BioPorto commences process to appoint new Chair of the Board of Directors COPENHAGEN, DENMARK, December 16, 2024 (GLOBE NEWSWIRE) – The Board of Directors of...
BioPorto offentliggør delårsresultater og opdatering for tredje kvartal og ni måneder af regnskabsåret 2024
14 nov. 2024 02h50 HE
|
BioPorto A/S
14. november 2024 Meddelelse nr. 22 BioPorto offentliggør delårsresultater og opdatering for tredje kvartal og ni måneder af regnskabsåret 2024 ...
BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024
14 nov. 2024 02h50 HE
|
BioPorto A/S
November 14, 2024Announcement no. 22 BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024 Revenue growth and strategic execution COPENHAGEN,...
BioPorto A/S inviterer til webcast
12 nov. 2024 03h57 HE
|
BioPorto A/S
12. november 2024 Pressemeddelelse BioPorto A/S inviterer til webcast KØBENHAVN, DANMARK og BOSTON, MA, USA, 12. november, 2024 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto eller Selskabet)...
BioPorto A/S to Host Third Quarter 2024 Earnings Webcast
12 nov. 2024 03h57 HE
|
BioPorto A/S
November 12, 2024 News release BioPorto A/S to Host Third Quarter 2024 Earnings Webcast COPENHAGEN, DENMARK and BOSTON, MA, USA, November 12, 2024 (GLOBE NEWSWIRE) – BioPorto A/S...
BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences
08 nov. 2024 11h03 HE
|
BioPorto A/S
8 November 2024 New Release BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare...
Grant of Warrants
04 nov. 2024 12h44 HE
|
BioPorto A/S
4 November 2024Announcement no. 21 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, November 4, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the...
Første patient indrulleret - BioPorto har påbegyndt indrullering til det amerikanske studie vedrørende ProNephro AKI (NGAL)™ til voksen brug ved Massachusetts General Hospital
29 oct. 2024 03h56 HE
|
BioPorto A/S
29. oktober 2024Selskabsmeddelelse nr. 20 Første patient indrulleret - BioPorto har påbegyndt indrullering til det amerikanske studie vedrørende ProNephro AKI (NGAL)™ til voksen brug ved...
First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital
29 oct. 2024 03h56 HE
|
BioPorto A/S
October 29, 2024Announcement no. 20 First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital COPENHAGEN,...
BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests
28 oct. 2024 11h26 HE
|
BioPorto A/S
28 October 2024Announcement no. 19 BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests COPENHAGEN, DENMARK and BOSTON, MA, USA,...